Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - FatPipe, Inc. (FATN) increased by 76% to $3.24 [3] - FiEE, Inc. (FIEE) rose by 25% to $6.45 [3] - Teradyne, Inc. (TER) saw a 22% increase, reaching $305.00 [3] - Sidus Space, Inc. (SIDU) gained 12%, trading at $2.89 [3] - Palantir Technologies Inc. (PLTR) was up 11% at $164.39 [3] - Namib Minerals (NAMM) also increased by 11% to $4.33 [3] - DaVita Inc. (DVA) rose by 10% to $122.94 [3] - TeraWulf Inc. (WULF) increased by 10% to $14.88 [3] - Hycroft Mining Holding Corporation (HYMC) saw an 8% rise to $38.27 [3] - Baiya International Group Inc. (BIYA) was up 6% at $4.29 [3] Premarket Losers - Psyence Biomedical Ltd. (PBM) decreased by 18% to $3.11 [4] - AsiaStrategy (SORA) fell by 17% to $2.30 [4] - Julong Holding Limited (JLHL) dropped 16% to $3.54 [4] - PS International Group Ltd. (PSIG) declined by 13% to $5.54 [4] - Rambus Inc. (RMBS) saw an 11% decrease, trading at $100.76 [4] - Intelligent Living Application Group Inc. (ILAG) was down 11% to $2.80 [4] - Phoenix Asia Holdings Limited (PHOE) fell by 8% to $16.05 [4] - La Rosa Holdings Corp. (LRHC) decreased by 8% to $2.25 [4] - Axalta Coating Systems Ltd. (AXTA) dropped 7% to $31.00 [4] - VivoSim Labs, Inc. (VIVS) was down 5% at $2.30 [4]

Core Insights - Psyence Biomedical Ltd. has established a Scientific Advisory Board (SAB) to enhance its expertise in psilocybin research and clinical trial design [1][3] - Dr. Albert P. Garcia-Romeu, a prominent researcher in psychedelics, will chair the SAB, bringing significant experience in psilocybin clinical trials [2][3] - The company is advancing its Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and is preparing for a second indication in Alcohol Use Disorder [3][4] Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, specifically nature-derived psilocybin [4] - The company aims to address unmet needs in mental health disorders, particularly in the context of Palliative Care [4] - Psyence is the first life science biotechnology company developing psilocybin-based psychedelic medicine to be listed on Nasdaq [4] Research and Development - The SAB will assist in designing the Phase III program for Adjustment Disorder while also preparing for Alcohol Use Disorder development [3] - Dr. Garcia-Romeu's involvement is expected to enhance the company's research capabilities in areas that have been largely overlooked by the pharmaceutical industry [4]